Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 846Carcinoma, Non-Small-Cell Lung 553Neoplasms 516Prostatic Neoplasms 503Lung Neoplasms 312Colorectal Neoplasms 304Multiple Myeloma 295Neoplasm Metastasis 255Melanoma 244Ovarian Neoplasms 215Leukemia, Myeloid, Acute 212Pancreatic Neoplasms 203Squamous Cell Carcinoma of Head and Neck 171Carcinoma, Renal Cell 166Stomach Neoplasms 160Recurrence 159Lymphoma 159Carcinoma, Hepatocellular 159Glioblastoma 151Brain Neoplasms 151Lymphoma, Non-Hodgkin 143Uterine Cervical Neoplasms 142Head and Neck Neoplasms 141Urinary Bladder Neoplasms 137Leukemia, Lymphocytic, Chronic, B-Cell 137Triple Negative Breast Neoplasms 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Colonic Neoplasms 117Lymphoma, Follicular 114

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Castration-sensitive Prostate Cancer × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡